(759) Transcutaneous Posterior Tibial Nerve Stimulation in Men vs Women with Overactive Bladder: Short-Term Efficacy and Quality-Of-Life Changes

Introduction Overactive bladder (OAB) significantly impacts patients’ quality of life, and many individuals experience insufficient benefit or poor tolerance to standard behavioral and pharmacologic therapies. Transcutaneous posterior tibial nerve stimulation (TTNS) is a noninvasive neuromodulation option, yet sex-specific treatment responses remain insufficiently studied; therefore, this study evaluates short-term TTNS outcomes in male and female OAB patients. Objective The primary objective of this study was to evaluate the short-term effectiveness of transcutaneous posterior tibial nerve stimulation (TTNS) in patients with overactive bladder (OAB). A secondary objective was to compare treatment outcomes between male and female patients in terms of symptom improvement and quality-of-life measures. Methods Overactive bladder (OAB) is a common condition that negatively affects quality of life, and transcutaneous posterior tibial nerve stimulation (TTNS) has emerged as a non-invasive therapeutic option. This prospective study evaluated short-term TTNS efficacy and sex-based treatment differences in patients with idiopathic OAB. A total of 74 patients (41 males, 33 females) treated between January 2024 and March 2025 were included. TTNS was administered twice weekly for six weeks using surface electrodes positioned posterior to the medial malleolus, with 10 Hz frequency, 200 μs pulse width, and 30-minute sessions. Symptom scores, urinary frequency, urge incontinence episodes, ICIQ-SF, and SF-12 scores were recorded before and after treatment. Both men and women demonstrated significant improvements in OAB symptom scores and quality-of-life measures. Urge incontinence decreased markedly in both groups, with a greater reduction observed in men. TTNS appears to be an effective, well-tolerated therapy for OAB, with notable benefit particularly in male patients. Results A total of 74 patients were included (41 males, 33 females). The mean age was 44.9 ± 8 years in males and 40.24 ± 13 years in females. Baseline OAB symptom scores were significantly higher in females compared to males (31.2 ± 5.6 vs. 26.4 ± 6; p=0.01). Following TTNS treatment, symptom scores improved significantly in both groups, decreasing to 14.3 ± 5 in males and 17.1 ± 5 in females (p=0.044). Before treatment, urge incontinence was present in 75% of males (n=31) and 72.7% of females (n=24). After treatment, urge incontinence decreased to 4.9% (n=2) in males and 24.2% (n=8) in females (p=0.015), indicating a more pronounced improvement in male patients. Overall, TTNS significantly improved urinary urgency, frequency, incontinence episodes, and patient-reported outcomes across both sexes, with male patients demonstrating a greater reduction in urge incontinence. Conclusions TTNS significantly improved OAB symptoms, urinary frequency, urge incontinence, and quality of life in both men and women. Male patients demonstrated a greater reduction in urge incontinence. TTNS appears to be a safe, effective, and well-tolerated non-invasive therapy. Disclosure No